Clinical trial of Echo Therapeutics' Symphony CGM System receives IRB approval

Published on May 21, 2013 at 9:03 AM · No Comments

Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® CGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, announced today that the Company's clinical trial of its Symphony CGM System has received Institutional Review Board (IRB) approval. The IRB approval enables the commencement of a clinical evaluation of Symphony that will support the Company's CE Mark Technical File.

"It's gratifying to see this important technology advance. This IRB approval signals a long-awaited CE Mark regulatory trial initiation," commented Dr. Mooney.  "Our team's hard work and extreme dedication have put us in a very strong position to begin the process of securing Symphony's market approval by European regulatory agencies."


Echo Therapeutics, Inc.

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
You might also like... ×
Research findings unveil new avenues to monitor, treat lung cancer more effectively